Warning letter
LifeSouth Community Blood Centers: warning letter of Jul 29, 2003
FDA warning letter UCM147616 · New Orleans District Office
Key facts
| Reference number | UCM147616 |
|---|---|
| Company | LifeSouth Community Blood Centers |
| Subject | GMP for Blood & Blood Components/Finished Pharmaceuticals |
| Issue date | Jul 29, 2003 |
| Posted date | Jul 29, 2003 |
| Issuing office | New Orleans District Office |
| Product type | Biologics |
| CFR sections cited | 211, 211.192, 211.22(a), 211.68(a), 211.100(a), 211.100(b), 606.160, 606.165, 606.100(b)(6), 606.100(c), 606.120(b)(3), 606.160(b)(1)(i) and 4 more |
| Country | 3 |
| Inspection city | Montgomery |
| Inspection ZIP | 36106-2803 |
| Inspection start date | Mar 12, 2003 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: